Novo Nordisk Partners With Anthropic to Expand AI Use in Drug Research

M&A · PartnershipProduct / Tech
โดย GuruFocus·DKUS·Read original
Summary · why it matters

Novo Nordisk said it has entered a partnership with Anthropic to expand the use of artificial intelligence in drug research and software development. The agreement is aimed at helping the Wegovy maker address key research challenges and potentially shorten parts of the medicine development process. As part of the collaboration, Novo Nordisk plans to evaluate Anthropic's Claude Science platform, a tool designed to support scientific research workflows, with initial work focused on applying AI to selected research and development activities. The Danish drugmaker also intends to use Anthropic's AI models to support software engineering efforts across the organization, and earlier this year formed a separate partnership with OpenAI focused on drug discovery and other business functions. The companies said the partnership includes data governance measures and human oversight, with Novo Nordisk CEO Mike Doustdar saying the deal supports the company's goal of becoming a more AI-focused healthcare organization and Anthropic CEO Dario Amodei saying advanced AI tools could help researchers improve the pace of scientific work.

Impact on stocks 1

Biotech & Genomic Medicine▲ · 1 stocks
Novo Nordisk A/S
NOV
▲ PositiveTechnologyrelevance

Novo Nordisk partners with Anthropic to apply AI (Claude Science) to drug research and software development, potentially shortening medicine development.

Theme Impact 3

Off-coverage companies 2

AnthropicPrivate▲ Positive
Demandrelevance

Anthropic's Claude Science platform and AI models are being adopted by Novo Nordisk for research and software engineering.

OpenAIPrivate± Mixed
relevance

Related news

Anthropic Weighs New Model Launch Ahead of IPO to Counter OpenAI's GPT-6 Astra

Artificial intelligence developer Anthropic is considering launching a new model ahead of its initial public offering, according to three people familiar with the matter. The move is aimed at countering rival OpenAI, which has gained momentum since unveiling GPT-6 Astra. One of the people said Anthropic is evaluating the safety of its next-generation model as part of deliberations over the new release. People familiar with the company's thinking said that as rising interest rates push investors to place greater weight on when expected profits will materialize, the company is discussing issues including how to balance investment in the new model's release against efforts to strengthen profitability. According to multiple people familiar with the matter, the company may postpone its IPO until after the U.S. midterm elections in November. Anthropic declined to comment.
Artificial Intelligence
ロイター·27mRead more →
2

OpenAI CEO Altman to Address AI Safety at UN Security Council Meeting

OpenAI CEO Sam Altman will speak about AI safety measures at a Security Council meeting next week, as world leaders gather in New York for the UN General Assembly. A company spokesperson confirmed the plan on the 18th, noting that the Security Council will hold a meeting on AI and international security on the 23rd. According to the spokesperson, Altman will discuss the need for international coordination and common safety standards, as well as the measures the company is taking. According to diplomatic sources, an Anthropic executive is also expected to attend the meeting, though this has not yet been finalized. Several AI industry executives have warned in recent weeks that AI could soon evolve autonomously and escape human control, and have called for a coordinated slowdown in development.
Artificial Intelligence
ロイター·1hRead more →
▲

UBS Flags AI Science Shift as Investment Theme After OpenAI Proof

UBS Wealth Management says artificial intelligence is moving beyond text generation into scientific research, opening investment opportunities across AI infrastructure, pharmaceuticals, nuclear fusion, industrial materials and utilities. The shift was highlighted by OpenAI's recent mathematical proof related to the Navier-Stokes equations, a centuries-old fluid dynamics problem and one of seven Millennium Prize Problems, which OpenAI tackled using 10,000 autonomous AI agents working in parallel for 88 hours before formalizing the proof with Lean, a system for machine-checked mathematical validation. In pharmaceuticals, multi-agent AI systems can simulate millions of protein variations in the cloud, and more than 170 AI-designed programs are already in development or clinical evaluation, including Phase III trials. In nuclear fusion, reinforcement-learning systems can predict plasma disruptions around 200 milliseconds before they occur and adjust magnetic coils thousands of times per second, while AI models in materials science can test millions of elemental combinations daily in search of properties for lighter, higher-density batteries, lower-heat computing hardware and potential room-temperature superconductors. The broader investment case centers on AI becoming a tool for automating scientific research rather than simply generating content, with companies exposed to AI infrastructure, pharmaceuticals, industrial materials and utilities positioned to benefit as these technologies move toward commercial applications.
GOOGLLYMSFTNVDAUBSG.SW
Biotech & Genomic Medicine ▲Artificial Intelligence ▲Fusion Energy ▲
Investing.com·3hRead more →
© 2026 MarketDXNews